Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: Results of a 16-week open-label trial

Journal of Alzheimer's Disease

Volumn 25, Issue 3, 2011, Pages 463-475

  Schulz, Jörg B ^a   Rainer, Michael ^b   Klünemann, Hans Hermann ^c   Kurz, Alexander ^d   Wolf, Stefanie ^a,e   Sternberg, Kati ^f   Tennigkeit, Frank ^f  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b DANUBE HOSPITAL   (Austria)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Alzheimer's disease; clinical trial; cognition; functional communication; memantine; once daily; open label

Indexed keywords

MEMANTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; CLINICAL TRIAL; COGNITION; COMMON COLD; COMMUNICATION SKILL; DEHYDRATION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SYNCOPE; TREATMENT OUTCOME;

EID: 79959682427     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-101929     Document Type: Article

References (23)

1. Bullock R, Hammond G (2003) Realistic expectations: the management of severe Alzheimer disease. Alzheimer Dis Assoc Disord 17 (Suppl 3), S80-S85. (Pubitemid 37205720)
2. Cummings JL (2004) Alzheimer's disease. N Engl J Med 351, 56-67.
3. Georges J, Jansen S, Jackson J, Meyrieux A, Sadowska A, Selmes M (2008) Alzheimer's disease in real life-the dementia carer's survey. Int J Geriatr Psychiatry 23, 546-551. (Pubitemid 351722116)
4. Visch Brink EG, van Rhee Temme W, Rietveld T, Krulder JW, Van Harskamp F, van der Cammen TJ (2009) Improvement of spontaneous speech in early stage Alzheimer's with rivastigmine. J Nutr Health Aging 13, 34-38.
5. Chandler MJ, Lacritz LH, Hynan LS, Barnard HD, Allen G, Deschner M, Weiner MF, Cullum CM (2005) A total score for the CERAD neuropsychological battery. Neurology 65, 102-106. (Pubitemid 40967783)
6. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessmentof Alzheimer's disease. Neurology 39, 1159-1165. (Pubitemid 19239715)
7. Bayles K, Tomoeda C (1994) The Functional Linguistic Communication Inventory. Canyonlands Publishing, Inc.
8. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grund-man M, Ferris S (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 (Suppl 2), S33-S39.
9. Galasko D, Schmitt F, Thomas R, Jin S, Bennett D; Alzheimer's Disease Cooperative Study (2005) Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. J Int Neuropsychol Soc 11, 446-453. (Pubitemid 41167182)
10. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH (1997) Validity and reliability of the Alzheimer's disease Cooperative Study Clinical Global Impression of Change. The Alzheimer's Disease - Cooperative Study. Alzheimer Dis Assoc Disord 11 (Suppl 2), S22-S32.
11. Troyer AK (2000) Normative data for clustering and switching on verbal fluency tasks. J Clin Exp Neuropsychol 22, 370-378. (Pubitemid 30490253)
12. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291, 317-324. (Pubitemid 38101604)
13. Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S (2006) Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14, 704-715. (Pubitemid 44196270)
14. Pomara N, Ott BR, Peskind E, Resnick EM (2007) Meman-tine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. Alzheimer Dis Assoc Disord 21, 60-64. (Pubitemid 46398957)
15. Emre M, Mecocci P, Stender K (2008) Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease. J Alzheimers Dis 14, 193-199. (Pubitemid 352040033)
16. Mecocci P, Bladström A, Stender K (2009) Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analysesof ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry 24, 532-538.
17. Koch HJ, Szecsey A, Haen E (2004) NMDA-antagonism (memantine) : an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia. Curr Pharm Des 10, 253-259. (Pubitemid 38072761)
18. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351, 2498-2508.
19. Gauthier S (2006) Managing discontinuation syndrome in patients with dementia. J Psychiatry Neurosci 31, 72.
20. Kwak YT, Han I-W, Suk S-H, Koo M-S (2009) Two cases of discontinuation syndrome following cessation of memantine. Geriatr Gerontol Int 9, 203-205.
21. Singh S, Dudley C (2003) Discontinuation syndrome following donepezil cessation. Int J Geriat Psychiatry 18, 282-284. (Pubitemid 36503036)
22. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50, 136-145.
23. Hofbauer RK, Saxton J, Woodward M, Gilchrist N, Potocnik F, Yu SY, Hsu H-A, Graham SM, Perhach JL (2009) Effects of memantine on functional communication in patients with moderate AD: results of a 12-week placebo-controlled trial. Alzheimer's Dis Relat Disord 5 (Suppl 1), Abst P1-Abst P271.